The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib
Adam S. Kittai(The Ohio State University Wexner Medical Center), Jennifer A. Woyach(The Ohio State University), Kyle A. Beckwith, Kerry A. Rogers(The Ohio State University), Seema A. Bhat(The Ohio State University), Michael R. Grever(Johns Hopkins University), David A. Bond(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Lynne V. Abruzzo(The University of Texas MD Anderson Cancer Center), Ying Huang(Marshall University), Cecelia Miller, Amy S. Ruppert(The Ohio State University), John C. Byrd(The Ohio State University), Nyla A. Heerema(The Ohio State University), Daniel Goldstein(The Ohio State University)
Cited by 61
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia
|The Journal of Experimental Medicine|2001|1.1k